Lipeng Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lipeng Tang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Guangjuan Zheng
State Key Laboratory of Dampness Syndrome of Chinese Medicine The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China
8 shared publications - Chuanjian Lu
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
7 shared publications Xirun Zheng
Department of Pathology The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China
4 shared publicationsBing Feng
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publicationsChutian Li
Department of Pathology
3 shared publicationsJie Zhao
State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Wiley in Cell Proliferation
- p. e70265
Immune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis
Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide. A more refined classification of these diseases is essential for enabling targeted therapeutic strategies. Traditional Chinese Medicine (TCM) is gaining increasing recognition globally, offering potential insights into disease heterogeneity. In this study, we performed comprehensive T cell receptor (TCR) and B cell receptor (BCR) repertoire sequencing in 59 participants, including patients with Ps, RA, UC and healthy controls. Patients were further stratified into Dampness and non‐Dampness groups based on standardized TCM diagnostic criteria. Repertoire composition, clonotype richness, diversity metrics, V gene usage and shared CDR3 patterns were analysed. Machine learning approaches (LASSO, GLM and OPLS‐DA) were applied to identify diagnostic biomarkers, followed by validation in an independent cohort. Compared with healthy controls, Ps, RA and UC patients exhibited reduced clonotype richness and diminished TCR/BCR diversity, indicating adaptive immune contraction. Dampness ZHENG‐specific alterations were observed, including selective IgK and IgL clonotype richness reduction in Ps with dampness, increased TRA/TRB diversity in RA with dampness, and elevated TRG clonotype counts/read proportions in UC with dampness. Stratification by Dampness ZHENG revealed distinct immune repertoire architectures characterized by increased D50 index, reduced proportions of large clones and preferential V gene usage, including TRAV20 , TRAV38‐2DV8 and TRAV8‐3 . Unsupervised dimensionality reduction demonstrated significant separation between Dampness and non‐Dampness groups across diseases. A three‐gene V‐segment model achieved an AUC of 0.804 and 74.7% accuracy in an independent validation cohort, supporting its potential utility as an objective biomarker for Dampness ZHENG. Our findings suggest that TCM‐based phenotyping may offer a meaningful approach for subgrouping autoimmune diseases, thereby providing a foundation for more syndrome differentiation‐based treatment strategies.
- 18 July 2026
- Published by Wiley in Cell Proliferation
- p. e70265
Open AccessImmune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis
Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide. A more refined classification of these diseases is essential for enabling targeted therapeutic strategies. Traditional Chinese Medicine (TCM) is gaining increasing recognition globally, offering potential insights into disease heterogeneity. In this study, we performed comprehensive T cell receptor (TCR) and B cell receptor (BCR) repertoire sequencing in 59 participants, including patients with Ps, RA, UC and healthy controls. Patients were further stratified into Dampness and non‐Dampness groups based on standardized TCM diagnostic criteria. Repertoire composition, clonotype richness, diversity metrics, V gene usage and shared CDR3 patterns were analysed. Machine learning approaches (LASSO, GLM and OPLS‐DA) were applied to identify diagnostic biomarkers, followed by validation in an independent cohort. Compared with healthy controls, Ps, RA and UC patients exhibited reduced clonotype richness and diminished TCR/BCR diversity, indicating adaptive immune contraction. Dampness ZHENG‐specific alterations were observed, including selective IgK and IgL clonotype richness reduction in Ps with dampness, increased TRA/TRB diversity in RA with dampness, and elevated TRG clonotype counts/read proportions in UC with dampness. Stratification by Dampness ZHENG revealed distinct immune repertoire architectures characterized by increased D50 index, reduced proportions of large clones and preferential V gene usage, including TRAV20 , TRAV38‐2DV8 and TRAV8‐3 . Unsupervised dimensionality reduction demonstrated significant separation between Dampness and non‐Dampness groups across diseases. A three‐gene V‐segment model achieved an AUC of 0.804 and 74.7% accuracy in an independent validation cohort, supporting its potential utility as an objective biomarker for Dampness ZHENG. Our findings suggest that TCM‐based phenotyping may offer a meaningful approach for subgrouping autoimmune diseases, thereby providing a foundation for more syndrome differentiation‐based treatment strategies.
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 411-428
The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2– 3% of the global population, frequently co-occurs with depression. This highly prevalent comorbidity significantly impairs patients’ quality of life. Despite the substantial physical and mental health burden imposed by psoriatic depression, the underlying pathophysiological mechanisms connecting psoriasis and depression remain poorly understood. In this review, we explored several pathological processes that may contribute to psoriasis-associated depression, including immune cells dysregulations, hormones imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysfunctions, neuropeptides expression abnormalities, and gut dysbiosis. The primary purpose of this review was to present a comprehensive overview of the pathogenic mechanisms linking psoriasis and depression. These insights may guide trans-disciplinary interventions aimed at both skin and mood symptoms.
- 1 August 2025
- Published by Taylor & Francis in Psoriasis: Targets and Therapy
- Vol. ume 15, 411-428
Open AccessThe Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2– 3% of the global population, frequently co-occurs with depression. This highly prevalent comorbidity significantly impairs patients’ quality of life. Despite the substantial physical and mental health burden imposed by psoriatic depression, the underlying pathophysiological mechanisms connecting psoriasis and depression remain poorly understood. In this review, we explored several pathological processes that may contribute to psoriasis-associated depression, including immune cells dysregulations, hormones imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysfunctions, neuropeptides expression abnormalities, and gut dysbiosis. The primary purpose of this review was to present a comprehensive overview of the pathogenic mechanisms linking psoriasis and depression. These insights may guide trans-disciplinary interventions aimed at both skin and mood symptoms.
- Open Access
- 13 August 2024
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 15 (5) , 548-558
Yinxieling attenuates psoriasis in mice by regulating oxidative stress and lipid mediators to correct immune cell disorder through the NF-κB/Nrf2 signaling pathways
- 13 August 2024
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 15 (5) , 548-558
Open AccessYinxieling attenuates psoriasis in mice by regulating oxidative stress and lipid mediators to correct immune cell disorder through the NF-κB/Nrf2 signaling pathways
- Open Access
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (5) , 282-291
Upregulated SKP2 Empowers Epidermal Proliferation Through Downregulation of P27 Kip1
Tang L, et al. Ann Dermatol. 2024 May;36:e41. https://doi.org/10.5021/ad.23.118
- 1 January 2024
- Published by XMLink in Annals of Dermatology
- Vol. 36 (5) , 282-291
Open AccessUpregulated SKP2 Empowers Epidermal Proliferation Through Downregulation of P27 Kip1
Tang L, et al. Ann Dermatol. 2024 May;36:e41. https://doi.org/10.5021/ad.23.118
- Open Access
- 26 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 817526
Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion
Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation and epidermal hyperplasia. Punicalagin (PUN) is a main active ingredient of pomegranate (Punica granatum L.) peel with multiple biological activities, such as antibacterial, antioxidant and anti-tumor effects. However, the potential effect of PUN on psoriasis remains unknown. In this study, we want to investigate the pharmacological effect of PUN on psoriasis by using imiquimod (IMQ)-induced psoriatic mice model in vivo and tumor necrosis factor a (TNF-α) and interleukin-17A (IL-17A)-stimulated HaCaT cells in vitro. Our results showed that PUN can effectively alleviate the severity of psoriasis-like symptoms. Mechanistically, PUN potently suppresses the aberrant upregulation of interleukin-1β (IL-1β) and subsequent IL-1β-mediated inflammatory cascade in keratinocytes by inhibiting the nuclear factor kappa B (NF-κB) activation and cleaved caspase-1 expression in vitro and in vivo. Taken together, our findings indicate that PUN can relieve psoriasis by repressing NF-κB-mediated IL-1β transcription and caspase-1-regulated IL-1β secretion, which provide evidence that PUN might represent a novel and promising candidate for the treatment of psoriasis.
- 26 January 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 817526
Open AccessPunicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion
Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation and epidermal hyperplasia. Punicalagin (PUN) is a main active ingredient of pomegranate (Punica granatum L.) peel with multiple biological activities, such as antibacterial, antioxidant and anti-tumor effects. However, the potential effect of PUN on psoriasis remains unknown. In this study, we want to investigate the pharmacological effect of PUN on psoriasis by using imiquimod (IMQ)-induced psoriatic mice model in vivo and tumor necrosis factor a (TNF-α) and interleukin-17A (IL-17A)-stimulated HaCaT cells in vitro. Our results showed that PUN can effectively alleviate the severity of psoriasis-like symptoms. Mechanistically, PUN potently suppresses the aberrant upregulation of interleukin-1β (IL-1β) and subsequent IL-1β-mediated inflammatory cascade in keratinocytes by inhibiting the nuclear factor kappa B (NF-κB) activation and cleaved caspase-1 expression in vitro and in vivo. Taken together, our findings indicate that PUN can relieve psoriasis by repressing NF-κB-mediated IL-1β transcription and caspase-1-regulated IL-1β secretion, which provide evidence that PUN might represent a novel and promising candidate for the treatment of psoriasis.
- Open Access
- 29 September 2021
- Published by Wiley in Cell Proliferation
- Vol. 54 (11) , e13137
Pyroptosis: A promising therapeutic target for noninfectious diseases
Pyroptosis, which is characterized by gasdermin family protein‐mediated pore formation, cellular lysis and the release of pro‐inflammatory cytokines, is a form of programmed cell death associated with intracellular pathogens‐induced infection. However, emerging evidence indicates that pyroptosis also contributes to sterile inflammation. In this review, we will first illustrate the biological process of pyroptosis. Then, we will focus on the pathogenic effects of pyroptosis on multiple noninfectious disorders. At last, we will characterize several specific pyroptotic inhibitors targeting the pyroptotic signalling pathway. These data demonstrate that pyroptosis plays a prominent role in sterile diseases, thereby providing a promising approach to the treatment of noninfective inflammatory disorders.
- 29 September 2021
- Published by Wiley in Cell Proliferation
- Vol. 54 (11) , e13137
Open AccessPyroptosis: A promising therapeutic target for noninfectious diseases
Pyroptosis, which is characterized by gasdermin family protein‐mediated pore formation, cellular lysis and the release of pro‐inflammatory cytokines, is a form of programmed cell death associated with intracellular pathogens‐induced infection. However, emerging evidence indicates that pyroptosis also contributes to sterile inflammation. In this review, we will first illustrate the biological process of pyroptosis. Then, we will focus on the pathogenic effects of pyroptosis on multiple noninfectious disorders. At last, we will characterize several specific pyroptotic inhibitors targeting the pyroptotic signalling pathway. These data demonstrate that pyroptosis plays a prominent role in sterile diseases, thereby providing a promising approach to the treatment of noninfective inflammatory disorders.
- Open Access
- 1 January 2020
- Published by Wiley in Clinical & Translational Immunology
- Vol. 9 (10)
Emerging insights on the role of gasdermins in infection and inflammatory diseases
The gasdermins, family of pore‐forming proteins, are emerging key regulators of infection, autoinflammation and antitumor immunity. Multiple studies have recently characterised their crucial roles in driving pyroptosis, a lytic pro‐inflammatory type of cell death. Additionally, gasdermins also act as key effectors of NETosis, secondary necrosis and apoptosis. In this review, we will address current understanding of the mechanisms of gasdermin activation and further describe the protective and detrimental roles of gasdermins in host defence and autoinflammatory diseases. These data suggest that gasdermins play a prominent role in innate immunity and autoinflammatory disorders, thereby providing potential new therapeutic avenues for the treatment of infection and autoimmune disease.
- 1 January 2020
- Published by Wiley in Clinical & Translational Immunology
- Vol. 9 (10)
Open AccessEmerging insights on the role of gasdermins in infection and inflammatory diseases
The gasdermins, family of pore‐forming proteins, are emerging key regulators of infection, autoinflammation and antitumor immunity. Multiple studies have recently characterised their crucial roles in driving pyroptosis, a lytic pro‐inflammatory type of cell death. Additionally, gasdermins also act as key effectors of NETosis, secondary necrosis and apoptosis. In this review, we will address current understanding of the mechanisms of gasdermin activation and further describe the protective and detrimental roles of gasdermins in host defence and autoinflammatory diseases. These data suggest that gasdermins play a prominent role in innate immunity and autoinflammatory disorders, thereby providing potential new therapeutic avenues for the treatment of infection and autoimmune disease.
- Open Access
- 6 October 2019
- Published by Wiley in Cell Proliferation
- Vol. 53 (1) , e12698
Long non‐coding RNAs in cutaneous biology and proliferative skin diseases: Advances and perspectives
Advances in transcriptome sequencing have revealed that the genome fraction largely encodes for thousands of non‐coding RNAs. Long non‐coding RNAs (lncRNAs), which are a class of non–protein‐coding RNAs longer than approximately 200 nucleotides in length, are emerging as key epigenetic regulators of gene expression recently. Intensive studies have characterized their crucial roles in cutaneous biology and diseases. In this review, we address the promotive or suppressive effects of lncRNAs on cutaneous physiological processes. Then, we focus on the pathogenic role of dysfunctional lncRNAs in a variety of proliferative skin diseases. These evidences suggest that lncRNAs have indispensable roles in the processes of skin biology. Additionally, lncRNAs might be promising biomarkers and therapeutic targets for cutaneous disorders.
- 6 October 2019
- Published by Wiley in Cell Proliferation
- Vol. 53 (1) , e12698
Open AccessLong non‐coding RNAs in cutaneous biology and proliferative skin diseases: Advances and perspectives
Advances in transcriptome sequencing have revealed that the genome fraction largely encodes for thousands of non‐coding RNAs. Long non‐coding RNAs (lncRNAs), which are a class of non–protein‐coding RNAs longer than approximately 200 nucleotides in length, are emerging as key epigenetic regulators of gene expression recently. Intensive studies have characterized their crucial roles in cutaneous biology and diseases. In this review, we address the promotive or suppressive effects of lncRNAs on cutaneous physiological processes. Then, we focus on the pathogenic role of dysfunctional lncRNAs in a variety of proliferative skin diseases. These evidences suggest that lncRNAs have indispensable roles in the processes of skin biology. Additionally, lncRNAs might be promising biomarkers and therapeutic targets for cutaneous disorders.
- 14 September 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (4) , 3661-3674
Downregulated miR‐187 contributes to the keratinocytes hyperproliferation in psoriasis
Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation. However, the pathogenesis of psoriasis is multifactorial and is not fully understood. MicroRNAs (miRNAs) represent a promising class of small, noncoding RNA molecules that have a large impact on cellular functions by regulating gene expression. Here we reported that microRNA‐187 (miR‐187), which is one of the most dynamic microRNAs identified in the deep screening miRNAs profile, is downregulated in inflammatory cytokines‐stimulated keratinocytes and psoriatic skins. By luciferase activity assay and gain‐of‐function studies, we showed that miR‐187 inhibits keratinocytes hyperproliferation by targeting CD276. Moreover, overexpression of miR‐187 decreases acanthosis and reduces the disease severity in psoriasis mouse models. Taken together, the results of our study implies miR‐187 as a critical factor in psoriasis pathogenesis, which could be a potent target for psoriasis treatment.
- 14 September 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (4) , 3661-3674
Downregulated miR‐187 contributes to the keratinocytes hyperproliferation in psoriasis
Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inflammation. However, the pathogenesis of psoriasis is multifactorial and is not fully understood. MicroRNAs (miRNAs) represent a promising class of small, noncoding RNA molecules that have a large impact on cellular functions by regulating gene expression. Here we reported that microRNA‐187 (miR‐187), which is one of the most dynamic microRNAs identified in the deep screening miRNAs profile, is downregulated in inflammatory cytokines‐stimulated keratinocytes and psoriatic skins. By luciferase activity assay and gain‐of‐function studies, we showed that miR‐187 inhibits keratinocytes hyperproliferation by targeting CD276. Moreover, overexpression of miR‐187 decreases acanthosis and reduces the disease severity in psoriasis mouse models. Taken together, the results of our study implies miR‐187 as a critical factor in psoriasis pathogenesis, which could be a potent target for psoriasis treatment.
- 10 February 2018
- Published by Wiley in Experimental Dermatology
- Vol. 27 (3) , 268-275
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3
The discovery of new therapeutic drugs with the efficacious and safe ability to prevent epidermal hyperplasia is extremely urgent for psoriasis. Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on psoriasis have not been reported. Here, we investigated the therapeutic effects of CTS on imiquimod (IMQ)‐induced psoriatic‐like skin model and explored the underlying mechanisms. Our results revealed that CTS effectively alleviates IMQ‐induced epidermal hyperplasia. In vitro studies also indicated that CTS potently inhibits the growth of keratinocytes. We further found that STAT3, a transcription factor for the cell growth, is the key mediator of CTS on the proliferation of keratinocytes. Taken together, our findings indicated that the curative effects of CTS on psoriasis are accomplished mainly through modulating STAT3, which providing evidences to develop CTS as a potential therapeutic agent for patients with psoriasis.
- 10 February 2018
- Published by Wiley in Experimental Dermatology
- Vol. 27 (3) , 268-275
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3
The discovery of new therapeutic drugs with the efficacious and safe ability to prevent epidermal hyperplasia is extremely urgent for psoriasis. Cryptotanshinone (CTS), an active component isolated from the root of Salvia miltiorrhiza Bunge, has been reported to have antibacterial and antitumor effects. However, its effects on psoriasis have not been reported. Here, we investigated the therapeutic effects of CTS on imiquimod (IMQ)‐induced psoriatic‐like skin model and explored the underlying mechanisms. Our results revealed that CTS effectively alleviates IMQ‐induced epidermal hyperplasia. In vitro studies also indicated that CTS potently inhibits the growth of keratinocytes. We further found that STAT3, a transcription factor for the cell growth, is the key mediator of CTS on the proliferation of keratinocytes. Taken together, our findings indicated that the curative effects of CTS on psoriasis are accomplished mainly through modulating STAT3, which providing evidences to develop CTS as a potential therapeutic agent for patients with psoriasis.